Fluorotronics, Inc. is a Global Innovation Company located in Vista, San Diego North County, California which commercializes, utilizes and explores a Fundamental Disruptive Technology based on Carbon-Fluorine Optical Platform called “Spectro-Fluor”. The patented and licensable Spectro-Fluor optical platform is a laser-based technology which uses and applies the discovered and developed Carbon-Fluorine Spectroscopy (CFS) method and family of proprietary devices called PLIRFA (Pulsed Laser Isochronic Raman and Fluorine/ Fluorescence Apparatus) which are intended for pharmaceutical, life sciences, biomedical, industrial, environmental and nanotechnology applications.
The optical molecular spectroscopy method developed by Fluorotronics detects, measures, characterizes, screens, monitors and images organofluorine (fluorinated) compounds and fluorine-labeled molecules, products and materials that contain C-F bond(s).
The Carbon-Fluorine Spectroscopy (CFS) method allows for detection, imaging and monitoring of Carbon-Fluorine bond in the way of its characteristic signatures discovered by inventors Professor Clay Sharts (Ph.D. California Institute of Technology, U.S. Navy Captain), Olga Sharts (M.S./M/S), optical scientist and chemist, and Dr. Vladimir Gorelik (Lebedev’s Physics Institute, Moscow, Russian Academy of Sciences), a Russian physicist.
The Spectro-Fluor technology pertaining to the needs of the $450B fluoroorganic and $1.6 trillion nanotechnology markets, specifically, regarding discovery, production, marketing, exploration and commercialization of fluoroorganic compounds, particular solutions and applications, for instance, regarding pharmaceutical product protection/counterfeiting market which is estimated to generate $675B. In general terms fluoroorganic (other name “organofluorine”) markets are highly diversified. “Fluoroorganic” means “containing a man-made chemical bond called Carbon-Fluorine bond (C-F bond)”.
For example, fluorinated molecules are widely used in the pharmaceutical industry for advanced drug design. In the pharmaceuticals area, approximately 220 fluorinated drugs were on the market in 1990, six years later, more than 1500 fluorine-containing drugs were under development.
A pioneer in fluoroanalytical detection and imaging as well as C-F tools and C-F nanomolecular reagents for Nanotechnology, Industrial, Pharmaceutical, Biomedical/Life Sciences and Security applications Fluorotronics is the first company to introduce and license a patented Carbon-Fluorine spectroscopy technology for molecular detection, measurement and imaging of compounds, materials or molecules containing carbon-fluorine bonds. This breakthrough Fundamental Disruptive Technology utilizes pulsed laser-based PLIRFA™ devices, to non-invasively detect carbon-fluorine (C-F) bonds and C-F -based (nano) molecular taggants across the entire fluoroorganic industrial and scientific applications.
Our Company is in the process of commercializing this breakthrough technology for research and industrial instrumentation, analytical, sensing, imaging, process analyzing methods, pharmaceutical, biomedical, life sciences segments, including stem cells research and applications; drug discovery and nanotechnology, drug safety and food and agricultural produce safety.
Fluorotronics provides efficient, integrated and cost-effective solutions that address the product lifecycle in Nanotechnology, Pharmaceutical (discovery, safety, manufacturing, and post-marketing), Biomedical and other Life Science markets.
As a Global Innovation Technology Company Fluorotronics provides patented detection and measurement systems, methodology and associated services (Carbon-Fluorine spectroscopy methods, applications and PLIRFA™ devices) to the fluoroorganic industries and research communities worldwide.
The Spectro-Fluor technology platform and its CFS method utilize the unique properties of a C-F bond being explored as a useful utility.
Our products, methods, and solutions provide various advantages and functionalities. In many applications the Company uses C-F bond as markers, taggants and labels, for example, as C-F nanomolecular taggants/markers for molecular assays in a drug discovery process. In many instances the C-F bond is already present in the product due to the product developers’ design and, thus, can be detected and used for product discovery, evaluation and assurance, for monitoring, imaging and screening purposes. It can be used to secure product safety and integrity, for instance, to assure quality and authenticity of pharmaceuticals by distributors, packaging companies, retailers, pharmaceutical manufacturers and consumers of the purchased product, especially, if such drug is generic, or was purchased on-line and/or via retail system domestically or abroad.
Our vision is to become the global leader and innovations technology holding in providing integrated devices, solutions, products and services pertaining to diversified organofluorine, industrial, pharmaceutical, biomedical, life sciences and nanotechnology markets.
We serve the needs of such markets by supplying a variety of licensable solutions, and compact, laboratory and hybrid PLIRFA devices (fiber optic, high throughput), and developing applications, approaches and associated methodologies for our customers, partners and collaborators.
We provide the 7 “S-Pillars”:
- “Star” Technology – a Fundamental Disruptive Technology
- Stability, and
As published in the British Royal Society of Chemistry edition (Faraday Discussions, v. 149, 2011) , Spectro-Fluor technology based on Carbon-Fluorine Spectroscopy may become “a gold standard” technology for many biomedical, life sciences and pharmaceutical applications and will result in the unification of the discovery and process technology platforms as well as pharmacovigilance tools.
Fluorotronics systems can rapidly enhance analytical practices, loosen technical bottlenecks, speed up clinical trials and drug discovery, this will offer novel medical and diagnostic solutions, and provide effective anticounterfeit drug technology, anti-terrorism measures, and eventually improve significantly the healthcare for a large segment of population. The deployment of Fluorotronics technologies by various industries will result in significant reduction of most costs associated with discovery, exponential growth of innovation, will increase competitiveness, and will maintain and improve quality of the existing products. That will allow for keeping our environment and consumer products safer.
Our primary focus is technology commercialization, product manufacturing, research cooperation, licensing of the patented technology, delivery of instruments and products for the pharmaceutical, R&D, life sciences, biomedical segment and manufacturing process analysis.
The Company was founded by Olga Sharts, an accomplished international technologist and entrepreneur, the origins of the Company can be found here. For the Fluorotronics Team, please click here.